저분자 메틸셀룰로스를 이용한 난용성 약물 가용화에 대한 연구

Abstract

Taxotere® and Taxol® have been widely used in therapies of solid tumor and administered by intravenous (IV) injection. Docetaxel (DTX) and Paclitaxel (PTX) was the main ingredient of those products. To make that formulation, Cremorphor EL or Polysorbate 80 (Tween 80) and kinds of alcohols were essential for solving those hydrophobic chemicals drug and injected by IV infusion with saline solution. However, many side-effects related to nervous system or digestive system are reported because of those surfactants and alcohols. Therefore, development of biocompatible and biodegradable natural polysaccharide, methylcellulose were used as a material for solubilization of hydrophobic drugs without surfactants. Furthermore, the conventional high molecular weight methylcellulose could not be filtered through kidney and were accumulated in kidney which causes severe tox-icity in kidney. In this study, we develop enzyme treated low-molecular weight methylcellulose (LMwMC) which has higher bio-elimination than conventional polysaccharide. New formulation using LMwMC without surfactants show higher anti-tumor efficacy compared to formulation of Taxotere® in vitro and in vivo experimental system. Overall, our data demonstrate low-molecular weight methylcellulose as a new drug delivery material for solubilizing the hydrophobic drug without surfactants.